Primary Immunodeficiency Disorders News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

X4 Pharma Pulls In $27M for Immune Drug in Cancer, Rare Diseases - Xconomy



Xconomy
 
X4 Pharma Pulls In $27M for Immune Drug in Cancer, Rare Diseases 
Xconomy
The immune system can't fight disease if its cells don't reach their targets. In some cancers and rare immune deficiency disorders, immune cell levels are too low. X4 Pharmaceuticals has developed drugs that it says can help restore these counts to ...

 


First Clinical Data for X4P-001-RD Demonstrating Preliminary Activity in Patients with WHIM Syndrome will be ... - Business Wire (press release)



Endpoints News
 
First Clinical Data for X4P-001-RD Demonstrating Preliminary Activity in Patients with WHIM Syndrome will be ... 
Business Wire (press release)
WHIM syndrome is a primary immunodeficiency disease (?PID?) caused by genetic mutations in the CXCR4 receptor gene resulting in susceptibility to certain types of infections. WHIM is an abbreviation for the characteristic clinical symptoms of the ...
X4 Pharmaceuticals Secures $27 Million in Series B Financing Digital Journal

all 4 news articles » 


Americas Dominates the Primary Immunodeficiency Diseases Treatment Market - Technavio - Business Wire (press release)



Business Wire (press release)
 
Americas Dominates the Primary Immunodeficiency Diseases Treatment Market - Technavio 
Business Wire (press release)
The increase in FDA approval for newer indications is driving the growth in the primary immunodeficiency diseases treatment market. The advancement in product and process development will add a new dimension to the current IVIG market segment.

and more » 


Primary Immunodeficiency Diseases Treatment Market Landscape, Size and Forecast Analysis - MilTech



Primary Immunodeficiency Diseases Treatment Market Landscape, Size and Forecast Analysis 
MilTech
Primary immunodeficiency diseases or PIDDs are disorders where part of the body's immune system is missing or not functioning properly. They weaken the body's immune system, making the patient susceptible to infections and other health problems.

 


Adma Biologics Cmn (NASDAQ:ADMA) Sees Unusual Trading Volume in Its Shares - HugoPress



Weekly Register
 
Adma Biologics Cmn (NASDAQ:ADMA) Sees Unusual Trading Volume in Its Shares 
HugoPress
Trading volume for Adma Biologics Cmn was 580K in the last trading session. Overall, volume was up 200.64% over the stocks normal daily volume. Investors are feeling more bearish on the company lately if you consider the uptick in short interest. The ...
Comparing ADMA Biologics (ADMA) & Cidara Therapeutics (NASDAQ:CDTX) Dispatch Tribunal
Learn Why Aisling Capital Ii Lp Purchased Adma Biologics, Inc Stake? WeeklyHub
Adma Biologics Cmn (NASDAQ:ADMA) Sees Heavy Trading Volume with 580K Shares Changing Hands Highlight Press

all 30 news articles » 


Cue Biopharma Announces Strategic Research Collaboration and ... - Business Wire (press release)



Cue Biopharma Announces Strategic Research Collaboration and ... 
Business Wire (press release)
Cue Biopharma?, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human i.

and more » 


Intra-Cellular Therapies Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 2017 Society for ... - GlobeNewswire (press release)



Intra-Cellular Therapies Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 2017 Society for ... 
GlobeNewswire (press release)
14, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced poster presentations related to its ...

and more » 


Plasma Protein Therapeutics Market to become US$ 31.8 Billion by ... - satPRnews (press release)



Plasma Protein Therapeutics Market to become US$ 31.8 Billion by ... 
satPRnews (press release)
Transparency Market Research pegs the global plasma protein therapeutics market to reach US$31.8 bn by the end of 2024, from a valuation of US$18.5 bn in ...

and more » 


Local 4-Year-Old Boy's Cancer in Remission After Experimental ... - NBC 6 South Florida



NBC 6 South Florida
 
Local 4-Year-Old Boy's Cancer in Remission After Experimental ... 
NBC 6 South Florida
A local 4-year-old boy is being treated with an experimental stem cell treatment at the University of Miami's pediatric cancer center. NBC 6's Amanda Placensia ...

and more » 


Repeal of Orphan Drug Tax Credit is an "Unprecedented Step" - PR Newswire (press release)



NPR
 
Repeal of Orphan Drug Tax Credit is an "Unprecedented Step" 
PR Newswire (press release)
Plasma protein therapies are life-saving treatments for persons facing particularly rare conditions, including Primary Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, bleeding disorders such as Hemophilia, Hereditary ...
NORD Issues Statement in Response to Proposed Repeal of the Orphan Drug Tax Credit National Organization for Rare Disorders

all 8 news articles »